TY - JOUR
T1 - 96-74: BioMonitor 2 Pilot Study
T2 - Subcutaneous Electrocardiograms Transmitted by Home Monitoring
AU - Ng, Ben
AU - Singarayar, Suresh
AU - Hellestrand, Kevin
AU - Illies, Peter
AU - Mohamed, Uwais
AU - Razak, Shakeeb
AU - Weerasooriya, Rukshen
AU - Ooi, Sze-Yuan
PY - 2016/6
Y1 - 2016/6
N2 - Purpose of the study: The BioMonitor 2 Pilot Study was a first-in-human study investigating the second generation insertable cardiac monitor, the BioMonitor 2 (Biotronik, Berlin, Germany). Here, we report the detection of arrhythmias, and the remote monitoring transmission. Method used: This was a prospective, multi-center, single-arm study in 5 sites across Australia. The BioMonitor 2 automatically detects atrial fibrillation, bradycardia, sudden rate drops, asystole and high ventricular rate episodes. It can store up to 54 subcutaneous ECG (sECG) episodes, with capacity to transmit up to 6 per day. Here, we analyse the episodes which were transmitted by the Home Monitoring system. The observation period totalled 588 patient-days, with 21 patients observed for 28 days after they received optimised device software. Summary of results: Most patients received the device for the investigation of atrial arrhythmias (48%) or syncope (38%). 16 patients (76%) transmitted at least one sECG. The median number of sECGs per patient was 7 (Interquartile range [IQR] 3-37). From 2 patients, more episodes were transmitted within 28 days than the device could store (78 and 128, respectively). During the observation period, 391 sECGs were transmitted on 129 patient-days (22% of the observation period), with a median of 2 sECGs per day (IQR 1-5). On 40 of these days (31%), episodes of more than one arrhythmia type were transmitted. Conclusion: We conclude that the daily transmission of multiple episodes may be helpful in the management of patients with an indication for an insertable cardiac monitor. More than one episode was detected on over half of the days with arrhythmias, and frequently, different arrhythmia types were detected within one day. The ability to automatically transmit up to 6 sECGs per day may make clinically relevant information available in time, and additionally prevent episodes from being lost due to memory limitations.
AB - Purpose of the study: The BioMonitor 2 Pilot Study was a first-in-human study investigating the second generation insertable cardiac monitor, the BioMonitor 2 (Biotronik, Berlin, Germany). Here, we report the detection of arrhythmias, and the remote monitoring transmission. Method used: This was a prospective, multi-center, single-arm study in 5 sites across Australia. The BioMonitor 2 automatically detects atrial fibrillation, bradycardia, sudden rate drops, asystole and high ventricular rate episodes. It can store up to 54 subcutaneous ECG (sECG) episodes, with capacity to transmit up to 6 per day. Here, we analyse the episodes which were transmitted by the Home Monitoring system. The observation period totalled 588 patient-days, with 21 patients observed for 28 days after they received optimised device software. Summary of results: Most patients received the device for the investigation of atrial arrhythmias (48%) or syncope (38%). 16 patients (76%) transmitted at least one sECG. The median number of sECGs per patient was 7 (Interquartile range [IQR] 3-37). From 2 patients, more episodes were transmitted within 28 days than the device could store (78 and 128, respectively). During the observation period, 391 sECGs were transmitted on 129 patient-days (22% of the observation period), with a median of 2 sECGs per day (IQR 1-5). On 40 of these days (31%), episodes of more than one arrhythmia type were transmitted. Conclusion: We conclude that the daily transmission of multiple episodes may be helpful in the management of patients with an indication for an insertable cardiac monitor. More than one episode was detected on over half of the days with arrhythmias, and frequently, different arrhythmia types were detected within one day. The ability to automatically transmit up to 6 sECGs per day may make clinically relevant information available in time, and additionally prevent episodes from being lost due to memory limitations.
U2 - 10.1093/europace/18.suppl_1.i80a
DO - 10.1093/europace/18.suppl_1.i80a
M3 - Abstract/Meeting Abstract
SN - 1099-5129
VL - 18
SP - i80-i80
JO - Europace
JF - Europace
IS - suppl_1
ER -